For research use only. Not for therapeutic Use.
Dirlotapide (Cat.No:I006495) is a gut-selective microsomal triglyceride transfer protein (MTTP or MTP) inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine. Dirlotapide is a drug used to treat obesity in dogs.
| Catalog Number | I006495 |
| CAS Number | 481658-94-0 |
| Synonyms | Dirlotapide; Slentrol; CP 742033; CP-742033; CP742033; CP-742,033.;(S)-N-(2-(benzyl(methyl)amino)-2-oxo-1-phenylethyl)-1-methyl-5-(4/’-(trifluoromethyl)-[1,1/’-biphenyl]-2-carboxamido)-1H-indole-2-carboxamide |
| Molecular Formula | C40H33F3N4O3 |
| Purity | ≥95% |
| Target | Microsomal Triglyceride Transfer Protein (MTP) |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | N-[(1S)-2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]-1-methyl-5-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]indole-2-carboxamide |
| InChI | InChI=1S/C40H33F3N4O3/c1-46(25-26-11-5-3-6-12-26)39(50)36(28-13-7-4-8-14-28)45-38(49)35-24-29-23-31(21-22-34(29)47(35)2)44-37(48)33-16-10-9-15-32(33)27-17-19-30(20-18-27)40(41,42)43/h3-24,36H,25H2,1-2H3,(H,44,48)(H,45,49)/t36-/m0/s1 |
| InChIKey | TUOSYWCFRFNJBS-BHVANESWSA-N |
| SMILES | O=C(C(N1C)=CC2=C1C=CC(NC(C3=CC=CC=C3C4=CC=C(C(F)(F)F)C=C4)=O)=C2)N[C@@H](C5=CC=CC=C5)C(N(C)CC6=CC=CC=C6)=O |
| Reference | </br>1:Dirlotapide as a model substrate to refine structure-based drug design strategies on CYP3A4-catalyzed metabolism. Sun H, Bessire AJ, Vaz A.Bioorg Med Chem Lett. 2012 Jan 1;22(1):371-6. doi: 10.1016/j.bmcl.2011.10.121. Epub 2011 Nov 6. PMID: 22094027 </br>2:Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide. Robinson RP, Bartlett JA, Bertinato P, Bessire AJ, Cosgrove J, Foley PM, Manion TB, Minich ML, Ramos B, Reese MR, Schmahai TJ, Swick AG, Tess DA, Vaz A, Wolford A.Bioorg Med Chem Lett. 2011 Jul 15;21(14):4150-4. doi: 10.1016/j.bmcl.2011.05.099. Epub 2011 Jun 2. PMID: 21684740 </br>3:Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America. Wren JA, Ramudo AA, Campbell SL, King VL, Eagleson JS, Gossellin J, Sunderland SJ.J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:81-9. PMID: 17567518 </br>4:An evaluation of dirlotapide to reduce body weight of client-owned dogs in two placebo-controlled clinical studies in Europe. Gossellin J, McKelvie J, Sherington J, Wren JA, Eagleson JS, Rowan TG, Sunderland SJ.J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:73-80. PMID: 17567517 </br>5:Influence of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on the digestibility of a dry expanded diet in adult dogs. Kirk CA, Boucher JF, Sunderland SJ, Wren JA.J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:66-72. PMID: 17567516 </br>6:Evaluation of dirlotapide for sustained weight loss in overweight Labrador retrievers. Gossellin J, Peachey S, Sherington J, Rowan TG, Sunderland SJ.J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:55-65. PMID: 17567515 </br>7:The safety of dirlotapide in dogs. Wren JA, King VL, Krautmann MJ, Gossellin J, Kerlin RL, Hickman MA, Schmahai TJ.J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:43-54. PMID: 17567514 </br>8:Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs. Wren JA, King VL, Campbell SL, Hickman MA.J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:33-42. PMID: 17567513 </br>9:Pharmacokinetics of dirlotapide in the dog. Merritt DA, Lynch MP, King VL.J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:24-32. PMID: 17567512 </br>10:Absorption, distribution, metabolism, and excretion of dirlotapide in the dog. Merritt DA, Bessire AJ, Vaz AD, Sams JP, Lynch MP.J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:17-23. PMID: 17567511 |
